tiprankstipranks
Trending News
More News >

Guardant Health price target raised to $57 from $52 at Scotiabank

Scotiabank raised the firm’s price target on Guardant Health (GH) to $57 from $52 and keeps an Outperform rating on the shares. The company’s Q1 revenues beat expectations, and its FY revenue guidance was raised, the analyst tells investors. The firm believes the company is well-positioned to deliver outsized growth, driven by its competitive strength, ASP growth, and real-world evidence platform.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1